Schering/Migenix Sign Deal For PEG-Intron Hepatitis C Combo Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering-Plough gains right to negotiate a licensing agreement for Migenix’ hepatitis C therapy celgosivir (MX-3253). Schering will provide pegylated interferon alfa-2b and ribavirin to Migenix for a Phase II combination study.